Raplon is a drug owned by Organon Usa Inc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 14, 2013. Details of Raplon's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5418226 | Monoquaternary 2,16-bispiperidinylandrostane derivatives |
Apr, 2013
(11 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Raplon is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Raplon's family patents as well as insights into ongoing legal events on those patents.
Raplon's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Raplon's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 14, 2013 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Raplon Generics:
There are no approved generic versions for Raplon as of now.
About Raplon
Raplon is a drug owned by Organon Usa Inc. Raplon uses Rapacuronium Bromide as an active ingredient. Raplon was launched by Organon Usa Inc in 1999.
Approval Date:
Raplon was approved by FDA for market use on 18 August, 1999.
Active Ingredient:
Raplon uses Rapacuronium Bromide as the active ingredient. Check out other Drugs and Companies using Rapacuronium Bromide ingredient
Dosage:
Raplon is available in injectable form for injection use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 100MG/VIAL | INJECTABLE | Discontinued | INJECTION |
| 200MG/VIAL | INJECTABLE | Discontinued | INJECTION |